H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on Corcept Therapeutics (CORT) to $60 from $67 and keeps a Buy rating on the shares. Given typical seasonality and Corcept’s pharmacy transition at the start of 2026, the firm expects a 19% sequential decline in the company’s Q1 sales.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics reports Q4 EPS 20c, consensus 33c
- Corcept Therapeutics Posts Strong 2025 Results, Issues Optimistic Outlook
- Corcept Therapeutics price target lowered to $67 from $105 at H.C. Wainwright
- Corcept Faces Appellate Setback in Korlym Patent Dispute
- Corcept ‘disappointed’ in court ruling over Teva patent dispute